In this large randomized trial, medical inpatients were randomized to apixaban (2.5mg orally BID) for 30 days, or enoxaparin (at least 20mg SQ qday) for 6-14 days. The primary outcome (30 day VTE death, PE, or DVT) was not significantly different between the groups, but the major bleeding rates were higher with apixaban. Apixaban should not be added to the palate of VTE prophylaxis options for medical patients (abstract).
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment